Targeting drugs across the blood brain barrier (BBB) is dependent on efficient delivery systems [1–4]. Certain drugs such as short peptide sequences show promising, medically relevant, biological responses for the treatment of Alzheimer’s disease (AD) but they have limited ability of reaching the brain [5–7].